Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Stock analysts at HC Wainwright boosted their FY2024 EPS estimates for Cardiol Therapeutics in a research report issued on Wednesday, December 18th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings per share of ($0.37) for the year, up from their previous forecast of ($0.38). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics' Q4 2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.33) EPS.
Cardiol Therapeutics Price Performance
CRDL traded down $0.03 during trading on Friday, reaching $1.28. The stock had a trading volume of 406,091 shares, compared to its average volume of 418,361. The stock has a 50 day moving average of $1.69 and a two-hundred day moving average of $1.96. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $104.58 million, a price-to-earnings ratio of -3.28 and a beta of 0.83. Cardiol Therapeutics has a 1-year low of $0.79 and a 1-year high of $3.12.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Foundations Investment Advisors LLC bought a new position in shares of Cardiol Therapeutics during the 2nd quarter valued at about $97,000. AdvisorShares Investments LLC lifted its stake in Cardiol Therapeutics by 12.7% during the second quarter. AdvisorShares Investments LLC now owns 1,466,972 shares of the company's stock valued at $2,934,000 after purchasing an additional 164,994 shares during the last quarter. Lion Street Advisors LLC boosted its holdings in Cardiol Therapeutics by 7.9% during the third quarter. Lion Street Advisors LLC now owns 273,281 shares of the company's stock worth $544,000 after buying an additional 20,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in Cardiol Therapeutics in the third quarter worth approximately $27,000. Finally, Townsquare Capital LLC acquired a new position in Cardiol Therapeutics in the third quarter worth approximately $27,000. 12.49% of the stock is owned by institutional investors and hedge funds.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
